Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Operating Leases: 2020-2024

Historic Operating Leases for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $187,000.

  • Mereo BioPharma Group's Operating Leases fell 79.36% to $187,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $187,000, marking a year-over-year decrease of 79.36%. This contributed to the annual value of $187,000 for FY2024, which is 79.36% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Operating Leases stood at $187,000 for FY2024, which was down 79.36% from $906,000 recorded in FY2023.
  • Mereo BioPharma Group's Operating Leases' 5-year high stood at $2.4 million during FY2021, with a 5-year trough of $187,000 in FY2024.
  • Its 3-year average for Operating Leases is $857,333, with a median of $906,000 in 2023.
  • Per our database at Business Quant, Mereo BioPharma Group's Operating Leases soared by 59.00% in 2021 and then tumbled by 79.36% in 2024.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Operating Leases stood at $1.5 million in 2020, then surged by 59.00% to $2.4 million in 2021, then tumbled by 37.45% to $1.5 million in 2022, then plummeted by 38.74% to $906,000 in 2023, then crashed by 79.36% to $187,000 in 2024.